肿瘤坏死因子-α、白细胞介素-6和脓毒症

[1] Spittler A,Razenberger M,Kupper H,et al.Relationship between interleukin-6 plasma concentration in patients with sepsis,monocyte phenotype,monocyte phagocytic properties,and cytokine production. Clinical Infectious Diseases . 2000

[2] Meyer TA,Wang J,Tiao GM,et al.Sepsis and endotoxendia stimulate intestinal interleukin 6 production. Journal of Surgery . 1995

[3] Hadjiminas DJ,McMasters KM,Peyton JC,et al.Tissue tumor necrosis factor mRNA expression following cecal ligation and puncture or intraperitoneal injection of endstzxin. Journal of Surgical Research . 1994

[4] Patel RT,Deen KI,Youngs D,et al.Interleukin 6 is a prognostic indicator of outcome in severe intra abdominal sepsis. British Journal of Surgery . 1994

[5] Cybulsky MI,Chan MK,Morat HZ,et al.Acute inflammation and microthrombosis indued by endotoxin, interleukin-1, and tumor necrosis factor and their implication in gram negative infection. Laboratory Investigation . 1988

[6] Tracey KJ,Fong Y,Hesse DG,et al.Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature . 1987

[7] Bone RC.Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatoy response syndrome(SIRS) and the multiple organ dysfuncion syndrome ( MODS). Annals of Internal Medicine . 1996

[8] Pohlman TH,Stanness KA,Beatty PG,et al.An endothelial cell surface factor(s) induced in vitro by lipopolysaccharide, interleukin1, and tumor necrosis factor increases neutrophil adherence by a CD18-dependent machanism. J Immunol . 1986

[9] Bone RC,Balk RA,Cerra FB,et al.Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest . 1992

[10] Vincent JL.Search for effective immunomodulating strategies against sepsis. The Lancet . 1998

[1] Spittler A,Razenberger M,Kupper H,et al.Relationship between interleukin-6 plasma concentration in patients with sepsis,monocyte phenotype,monocyte phagocytic properties,and cytokine production. Clinical Infectious Diseases . 2000

[2] Meyer TA,Wang J,Tiao GM,et al.Sepsis and endotoxendia stimulate intestinal interleukin 6 production. Journal of Surgery . 1995

[3] Hadjiminas DJ,McMasters KM,Peyton JC,et al.Tissue tumor necrosis factor mRNA expression following cecal ligation and puncture or intraperitoneal injection of endstzxin. Journal of Surgical Research . 1994

[4] Patel RT,Deen KI,Youngs D,et al.Interleukin 6 is a prognostic indicator of outcome in severe intra abdominal sepsis. British Journal of Surgery . 1994

[5] Cybulsky MI,Chan MK,Morat HZ,et al.Acute inflammation and microthrombosis indued by endotoxin, interleukin-1, and tumor necrosis factor and their implication in gram negative infection. Laboratory Investigation . 1988

[6] Tracey KJ,Fong Y,Hesse DG,et al.Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature . 1987

[7] Bone RC.Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatoy response syndrome(SIRS) and the multiple organ dysfuncion syndrome ( MODS). Annals of Internal Medicine . 1996

[8] Pohlman TH,Stanness KA,Beatty PG,et al.An endothelial cell surface factor(s) induced in vitro by lipopolysaccharide, interleukin1, and tumor necrosis factor increases neutrophil adherence by a CD18-dependent machanism. J Immunol . 1986

[9] Bone RC,Balk RA,Cerra FB,et al.Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest . 1992

[10] Vincent JL.Search for effective immunomodulating strategies against sepsis. The Lancet . 1998